Unformatted text preview: patients in the experimental drug group so as to provide more potential good for more patients (beneficence). (P6c) Dr. Kelley should enroll less patients (perhaps 1:10) in the placebo group so as to prevent harm to less patients by them not receiving any treatment (nonmaleficence). (P7) A clinical trial that does not uphold P1-P4 should be rejected. (P8) The clinical trial scenario would not uphold P1-P4 if it had the following features: (P8a) The same amount of patients should not continue to be enrolled in the experimental and placebo groups, given the expected success rate (violating Kantian autonomy). Therefore, Dr. Kelley ought to implement the system for clinical trials described in P6....
View Full Document
- Fall '09
- Kant, Clinical trial, Informed consent, Dr. Kelley